CALL US TODAY:
(305) 274-0221

Blog
24

  • Dec

  • 2018

images images Latest News images 0 Comments
Ixekizumab Compared With Adalimumab in Head-to-Head PsA Study

The SPIRIT H2H trial (N=566) randomized PsA patients to receive ixekizumab (160mg starting dose followed by 80mg every 4 weeks) or adalimumab (40mg every 2 weeks) for 52 weeks.

« Previous
Next »

Follow Us

  • LinkedIn
  • YouTube

Patient Portal

Pay Your Bill Online!

© 2024 Judith Crowell, MD and Associates


7800 SW 87th Avenue | Suite C-300 | Miami, Florida 33173

Designed By Emrah Interactive